Markets

Health Care Sector Update for 11/12/2014: CASI, OCUL, ALIM

Top Health-care stocks:

JNJ: -0.05%

PFE: flat

ABT: flat

MRK: -0.10%

AMGN: -0.26%

Health-care shares were generally lower in pre-market trade Wednesday.

In health-care stocks news, CASI Pharmaceuticals ( CASI ) said Wednesday that the China Food and Drug Administration (CFDA) has approved the biopharmaceutical company's application to conduct a Phase 2 clinical trial in soft tissue sarcoma patients in China with its proprietary drug candidate ENMD-2076.

This is CASI's second approval to begin a Phase 2 clinical trial in an oncology indication with ENMD-2076 in the country, followed by CFDA's approval in July to begin a Phase 2 trial in triple-negative breast cancer patients.

Shares in the company were unchanged at $1.60 during Wednesday's pre-market trading session. Over the past 52 weeks, the company has traded between $1.45 and $2.34.

Ocular Therapeutix, Inc. ( OCUL ), a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye, has announced enrollment of the first patients in a Phase 2b clinical trial evaluating Sustained Release Travoprost (OTX-TP) for the reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension.

Shares in the company were unchanged at $15.81 during Wednesday's pre-market trading session. Over the past 52 weeks, the company has traded between $11.90 and $16.97.

Alimera Sciences ( ALIM ) said the Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

Shares in the company were unchanged at $5.19 during Wednesday's pre-market trading session. Over the past 52 weeks, the company has traded between $1.76 and $8.44.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Copyright (C) 2016 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ALIM CASI OCUL

Other Topics

Commodities